Estudio de tratamientos combinados con pembrolizumab en cáncer de próstata metastásico resistente a la castración
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). There will be nine cohorts